Pharmacologic treatments for covid-19 patients
Methods
Protocol amendment:
As of March 1, 2022, the COVID-NMA revised its protocol to include only studies evaluating immunomodulators and antiviral therapies. Comparisons evaluating antivirals and immunomodulators will continue to be updated every two weeks.
For treatments that are neither immunomodulators nor antivirals, we provide the updated results up to Feb 28, 2022 including all identified reports through our search strategy up to this date.
meta-COVID
Perform your own analysis using COVID-NMA data, create and download your forest plots by clicking below:
Treatment comparisons
Of note, as of March 1, 2022, the COVID-NMA revised its protocol and reduced its scope.
Only comparisons evaluating antivirals and immunomodulators will continue to be updated every two weeks.
Create and download your forest plots with the most up-to-date data here Forest plots
Display new or updated analyses
Your research: comparisons updated with new studies
Access the forest plots for the 11 treatment comparisons .
Comparisons evaluating antivirals and immunomodulators updated every two weeks.
Anti-virals (5 comparisons)
Monoclonal antibodies (4 comparisons)
Other immunomodulators (1 comparisons)
Comparisons with last search date 28 February 2022 or as stated next to each comparison.
Other antimicrobials (antibiotics, antimalarials, antiparasitics) (1 comparisons)
Search studies
General characteristics of primary studies
Go to page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56
Page: 1 / Sorted by: Most recent ↓ | ||||||||
---|---|---|---|---|---|---|---|---|
Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
Treatment 1 | Treatment 2 | |||||||
New NCT04518410ACTIV-2 Taiwo BO, Top Antivir Med, 2022 Full text |
Not reported/unclear |
SAB-185 |
Placebo |
RCT | Outpatients with confirmed COVID-19 (mild-moderate) treated by 42 centers in the USA | N=213 | N/A | |
New NCT04518410ACTIV-2 Jilg N, Top Antivir Med, 2022 a Full text |
Not reported/unclear |
Camostat Mesilate |
Placebo |
RCT | Outpatients with confirmed COVID-19 (mild-moderate) treated by 54 centers in the USA | N=215 | N/A | |
New NCT04518410ACTIV-2 Evering TH, Open Forum Infect Dis, 2021 Full text Commentary |
Not reported/unclear |
BRII-196 plus BRII-198 |
Placebo |
RCT | Outpatients with confirmed COVID-19 (mild-moderate) treated by multiple centers in the USA, Brazil, South Africa, Mexico, Argentina and the Philippines. | N=837 |
Some concerns Details |
|
New NCT04709835 NCT04709835, Unpublished, 2022 Full text |
Not reported/unclear |
AT-527 AT-527 550 mg |
Placebo AT-527 1100 mg |
RCT | Outpatients with confirmed COVID-19 (mild-moderate) treated by 12 centers in Canada, Greece, Ireland, Latvia, Spain, UK | N=100 |
Some concerns Details |
|
New NCT04575038CRISIS2 CRISIS2, Unpublished, 2022 Full text |
Not reported/unclear |
Brequinar |
Placebo |
RCT | Outpatients with confirmed COVID-19 (mild) treated by 14 centers in USA. | N=115 |
Low Details |
|
NCT04694612 Adhikari P, Int J Infect Dis, 2022 b Full text Commentary |
Not reported/unclear |
Remdesivir |
Favipiravir |
RCT | Patients with confirmed COVID-19 (moderate) admitted to 9 centers in Nepal | N=20 |
Some concerns Details |
|
NCT04694612 Adhikari P, Int J Infect Dis, 2022 a Full text Commentary |
Not reported/unclear |
Favipiravir |
Placebo |
RCT | Patients with confirmed COVID-19 (mild) admitted to 9 centers in Nepal | N=70 |
Some concerns Details |
|
NCT04847141 NCT04847141, Unpublished, 2022 Full text |
Not reported/unclear |
Hyperimmune anti-COVID-19 Intravenous Immunoglobulin 1g/2g |
Placebo |
RCT | Outpatients with confirmed COVID-19 (asymptomatic) treated by 5 centers in Spain. | N=461 |
Some concerns Details |
|
NCT04427501 BLAZE-1 BLAZE-1, Unpublished, 2022 Full text |
Not reported/unclear |
LY-CoV555+LY-CoV016 |
Placebo |
RCT | Outpatients with confirmed COVID-19 (mild) treated by multiple centers in the USA. | N=354 |
Low Details |
|
IRCT20211004052664N1 Tehrani S, Mediterr J Infect Microbes Antimicrob, 2022 Full text Commentary |
No specific funding |
Favipiravir |
Standard care |
RCT | Outpatients with confirmed COVID-19 (moderate) treated by a single center in Iran. | N=78 |
Some concerns Details |